You can buy or sell Retrophin and other stocks, options, ETFs, and crypto commission-free!
Retrophin, Inc. Common Stock, also called Retrophin, is a biopharmaceutical company. Read More It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Yahoo FinanceMar 14
Retrophin (RTRX) Reports Q4 Loss, Misses Revenue Estimates
Retrophin (RTRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.07 per share a year ago.
Markets InsiderMar 5
Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor conferences in March: Cowen & Company 39th Annual Health Care Conference Date: Tuesday, March 12, 2019 Time: 8:00 a.m. ET Location: Boston, MA Barclays Global Healthcare Conference Date: Thursday, March 14, 2019 Time: 1:35 p.m. ET Location: Miami, FL Live webcasts will be available at https://ir.retrophin.com/e...
Stock Price, News, & Analysis for Retrophin
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal di...
Expected May 1, After Hours